Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reproxalap 0.25% in dry eye disease
NCT06493604Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Jun 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing Reproxalap 0.25% with Vehicle (2 arms). Primary endpoint: Ocular Discomfort Symptom Score at 100 minutes. Started Jun 2024; status: completed.
02
Drugs
reproxalap
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06493604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493604.